Cas no 2498-66-0 (Benzaanthracene-7,12-dione)
Benzaanthracene-7,12-dione Chemical and Physical Properties
Names and Identifiers
-
- Tetraphene-7,12-dione
- Benz[a]Anthracene-7,12-Dione
- 1,2-Benzanthraquinone
- 1,2-Benz[a]anthraquinone
- 1,2-BENZANTHRACHINON
- 1,2-BENZOANTHRAQUINONE
- Benz(a)anthracene-7,12-dione
- Benzanthracene-7,12-dione
- benzanthraquinone
- NAPHTHANTHRAQUINONE
- Sirius Yellow G
- C.I. 59000
- 7,12-Benz(a)anthraquinone
- Sirius Yellow G (VAN)
- BL89U5YZBK
- Benz[a]anthr
- CI-59000
- EINECS 219-693-8
- 7,12-dihydrotetraphene-7,12-dione
- Benzo[a]anthracene-7,12-dione #
- NSC-7961
- Benz[a]anthra-7,12-quinone
- 4-07-00-02644 (Beilstein Handbook Reference)
- DTXSID8051916
- Q27274742
- 1,2-Benzo-9,10-anthraquinone
- Benz[a]anthracene-7,12-quinone
- LHMRXAIRPKSGDE-UHFFFAOYSA-N
- FT-0606277
- SCHEMBL183078
- B0018
- J-015761
- NSC 7961
- Benzo[a]anthracene-7,12-dione
- AS-57440
- A817591
- NS00021076
- 2498-66-0
- NSC7961
- MFCD00003596
- D88588
- UNII-BL89U5YZBK
- Benz(a)anthracene-7,12-quinone
- Benz(a)anthra-7,12-quinone
- AKOS016008512
- BRN 2052941
- DTXCID3030478
- benz A anthracene-7,12-dione
- FB41611
- 219-693-8
- Benzaanthracene-7,12-dione
-
- MDL： MFCD00003596
- Inchi： 1S/C18H10O2/c19-17-13-7-3-4-8-14(13)18(20)16-12-6-2-1-5-11(12)9-10-15(16)17/h1-10H
- InChI Key： LHMRXAIRPKSGDE-UHFFFAOYSA-N
- SMILES： O=C1C2C=CC=CC=2C(C2C=CC3C=CC=CC=3C=21)=O
- BRN： 2052941
Computed Properties
- Exact Mass: 258.06800
- Monoisotopic Mass: 258.068
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 0
- Hydrogen Bond Acceptor Count: 2
- Heavy Atom Count: 20
- Rotatable Bond Count: 0
- Complexity: 427
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 0
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- Topological Polar Surface Area: 34.1
- Surface Charge: 0
- Tautomer Count: nothing
- XLogP3: 4.1
Experimental Properties
- Color/Form: Powder
- Density: 1.1584 (rough estimate)
- Melting Point: 166.0 to 171.0 deg-C
- Boiling Point: 361.53°C (rough estimate)
- Flash Point: 175.5±17.4 °C
- Refractive Index: 1.5200 (estimate)
- PSA: 34.14000
- LogP: 3.61520
- Solubility: Insoluble
- Vapor Pressure: 0.0±1.2 mmHg at 25°C
Benzaanthracene-7,12-dione Security Information
- Signal Word：warning
- Hazard Statement： H303 may be harmful by ingestion +h313 may be harmful by skin contact +h1106 may be harmful by inhalation
-
Warning Statement：
P264 wash thoroughly after treatment
p280 wear protective gloves / wear protective clothing / wear protective eye masks / wear protective masks
p305 if in eyes
p351 rinse carefully with water for a few minutes
p338 remove contact lenses (if any) and easy to operate, continue rinsing
p337 if eye irritation persists
p1086 get medical advice / care - Hazardous Material transportation number：2811
- WGK Germany：3
- Hazard Category Code： R36/37/38
- Safety Instruction： S26
- RTECS：CW4591000
-
Hazardous Material Identification：
- Safety Term：6.1(b)
- Packing Group：III
- Risk Phrases：R36/37/38
- Storage Condition：4° CStore…,-4℃Store…Better
- HazardClass：6.1(b)
- PackingGroup：III
- Packing Group：III
- Hazard Level：6.1(b)
Benzaanthracene-7,12-dione Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| TRC | B197940-5g |
Benz[a]anthracene-7,12-dione |
2498-66-0 | 5g |
$ 170.00 | 2023-04-19 | ||
| TRC | B197940-10g |
Benz[a]anthracene-7,12-dione |
2498-66-0 | 10g |
$ 299.00 | 2023-04-19 | ||
| TRC | B197940-25g |
Benz[a]anthracene-7,12-dione |
2498-66-0 | 25g |
$ 655.00 | 2023-04-19 | ||
| TRC | B197940-50g |
Benz[a]anthracene-7,12-dione |
2498-66-0 | 50g |
$ 1183.00 | 2023-04-19 | ||
| SHANG HAI MAI KE LIN SHENG HUA Technology Co., Ltd. | B869011-5g |
1,2-Benzanthraquinone |
2498-66-0 | 95% | 5g |
590.00 | 2021-05-17 | |
| SHANG HAI XIAN DING Biotechnology Co., Ltd. | B0018-5g |
Benzaanthracene-7,12-dione |
2498-66-0 | 95.0%(LC) | 5g |
￥915.0 | 2022-05-30 | |
| Apollo Scientific | OR54503-1g |
1,2-Benzanthraquinone |
2498-66-0 | 1g |
￡16.00 | 2025-02-20 | ||
| Apollo Scientific | OR54503-5g |
1,2-Benzanthraquinone |
2498-66-0 | 5g |
￡56.00 | 2025-02-20 | ||
| YUN NAN XI LI SHENG WU JI SHU GU FEN Co., Ltd. | BBP80712-5mg |
1,2-Benzanthraquinone |
2498-66-0 | 98.0% | 5mg |
￥150 | 2021-05-07 | |
| TI XI AI ( SHANG HAI ) HUA CHENG GONG YE FA ZHAN Co., Ltd. | B0018-5G |
1,2-Benzanthraquinone |
2498-66-0 | >95.0%(HPLC) | 5g |
￥560.00 | 2024-04-17 |
Benzaanthracene-7,12-dione Suppliers
Audited Supplier
Audited Supplier
Benzaanthracene-7,12-dione Related Literature
-
Esther S. Boll,Jens Nejrup,Julie K. Jensen,Jan H. Christensen Environ. Sci.: Processes Impacts 2015 17 606
-
Evangelos B. Bakeas,Georgios Karavalakis Environ. Sci.: Processes Impacts 2013 15 412
-
Uwayemi M. Sofowote,Laurie M. Allan,Brian E. McCarry J. Environ. Monit. 2010 12 417
-
4. Aromatic nucleophilic substitution of hydrogen: reactions of 6-nitroquinoline with potassium cyanide and nitroalkanesAle? Halama,Vladimír Machá?ek J. Chem. Soc. Perkin Trans. 1 1999 2495
-
Uwayemi M. Sofowote,Laurie M. Allan,Brian E. McCarry J. Environ. Monit. 2010 12 425
Additional information on Benzaanthracene-7,12-dione
Recent Advances in the Study of Benzaanthracene-7,12-dione (CAS: 2498-66-0) and Its Applications in Chemical Biology and Medicine
Benzaanthracene-7,12-dione (CAS: 2498-66-0) is a polycyclic aromatic hydrocarbon derivative that has garnered significant attention in recent years due to its unique chemical properties and potential applications in chemical biology and medicine. This compound, characterized by its anthracene core and quinone functionalities, has been the subject of numerous studies exploring its synthesis, reactivity, and biological activities. The latest research highlights its role as a promising scaffold for drug development, particularly in the fields of oncology and antimicrobial therapy.
Recent studies have focused on the synthesis and structural modification of Benzaanthracene-7,12-dione to enhance its bioactivity and selectivity. A 2023 publication in the Journal of Medicinal Chemistry demonstrated that introducing electron-withdrawing groups at specific positions of the anthracene ring significantly improved the compound's cytotoxicity against cancer cell lines, including MCF-7 and A549. The study also revealed that these modifications reduced off-target effects, suggesting a potential pathway for developing more selective anticancer agents.
In addition to its anticancer properties, Benzaanthracene-7,12-dione has shown remarkable antimicrobial activity. A recent study published in Bioorganic & Medicinal Chemistry Letters (2024) reported that derivatives of this compound exhibited potent inhibitory effects against methicillin-resistant Staphylococcus aureus (MRSA) and Candida albicans. The researchers attributed this activity to the compound's ability to disrupt microbial cell membranes and interfere with essential enzymatic processes. These findings open new avenues for addressing the growing challenge of antibiotic resistance.
The mechanism of action of Benzaanthracene-7,12-dione has been a key area of investigation. Advanced computational modeling and in vitro studies have elucidated its interactions with biological targets, such as DNA topoisomerases and redox-sensitive proteins. A 2024 study in Chemical Science utilized cryo-EM and X-ray crystallography to visualize the binding of Benzaanthracene-7,12-dione derivatives to the active site of topoisomerase II, providing atomic-level insights into its inhibitory mechanism. These structural insights are invaluable for rational drug design and optimization.
Despite these promising developments, challenges remain in the clinical translation of Benzaanthracene-7,12-dione-based therapies. Issues such as solubility, bioavailability, and potential toxicity need to be addressed through further structural optimization and formulation strategies. Recent advances in nanoparticle-based delivery systems, as reported in a 2023 Nature Communications article, offer potential solutions to these challenges by enhancing the compound's stability and targeted delivery.
In conclusion, Benzaanthracene-7,12-dione (CAS: 2498-66-0) represents a versatile and promising scaffold in chemical biology and medicinal chemistry. The latest research underscores its potential as a multitarget agent for cancer and infectious diseases, while also highlighting the need for continued investigation into its pharmacokinetics and safety profile. As synthetic methodologies and biological understanding advance, this compound is poised to play an increasingly important role in the development of novel therapeutic agents.
2498-66-0 (Benzaanthracene-7,12-dione) Related Products
- 58024-07-0(2-methyltetraphene-7,12-dione)
- 76319-75-0(Naphth[2,3-a]azulene-5,12-dione)
- 60184-76-1(Benz[a]anthracene-7,12-dione, 11-methyl-)
- 83244-76-2(Dibenzo[l,pqr]benz[a]anthracene-7,12-dione)
- 61533-50-4(benzo[a]tetracene-7,14-dione)
- 60451-76-5(Benz[a]anthracene-7,12-dione, 1-methyl-)
- 55024-84-5(Naphtho[1,2-a]anthracene-9,14-dione)
- 3719-43-5(benzo[k]tetraphene-7,14-dione)
- 3228-74-8( )
- 94464-93-4( )
